Invesco Ltd. Raises Stake in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Invesco Ltd. increased its holdings in Eyepoint Pharmaceuticals by 174.3%, acquiring an additional 27,291 shares and totaling 42,948 shares valued at $233,000 as of the latest SEC filing.
• Eyepoint Pharmaceuticals reported a quarterly loss of ($0.85) EPS, falling short of the consensus estimate of ($0.67), while total revenue for the quarter was $5.33 million, below expectations.
• The stock has a market capitalization of approximately $965.71 million, with a one-year price range between $3.91 and $14.37 per share.

Invesco Ltd. increased its holdings in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 174.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,948 shares of the company's stock after purchasing an additional 27,291 shares during the period. Invesco Ltd. owned 0.06% of Eyepoint Pharmaceuticals worth $233,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. California State Teachers Retirement System lifted its stake in shares of Eyepoint Pharmaceuticals by 3.8% in the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after acquiring an additional 1,797 shares during the period. Arizona State Retirement System lifted its stake in shares of Eyepoint Pharmaceuticals by 12.7% in the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock worth $90,000 after acquiring an additional 1,877 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Eyepoint Pharmaceuticals by 5.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 71,238 shares of the company's stock worth $531,000 after acquiring an additional 3,657 shares during the period. Wellington Management Group LLP lifted its stake in shares of Eyepoint Pharmaceuticals by 3.2% in the 4th quarter. Wellington Management Group LLP now owns 177,316 shares of the company's stock worth $1,321,000 after acquiring an additional 5,552 shares during the period. Finally, Cyndeo Wealth Partners LLC lifted its stake in shares of Eyepoint Pharmaceuticals by 48.6% in the 1st quarter. Cyndeo Wealth Partners LLC now owns 25,250 shares of the company's stock worth $137,000 after acquiring an additional 8,260 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on EYPT. Royal Bank Of Canada initiated coverage on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 target price for the company. Chardan Capital reiterated a "buy" rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Mizuho reduced their price objective on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. Finally, HC Wainwright raised their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $26.86.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ:EYPT traded up $0.02 during mid-day trading on Friday, hitting $13.35. 665,102 shares of the company's stock traded hands, compared to its average volume of 751,126. The firm's 50 day simple moving average is $11.11 and its 200 day simple moving average is $8.31. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $14.42. The company has a market cap of $920.22 million, a PE ratio of -4.98 and a beta of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The business had revenue of $5.33 million for the quarter, compared to analysts' expectations of $6.82 million. On average, research analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.